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Abstract
Background: The changes in gene expression profile as prostate cancer progresses from an
androgen-dependent disease to an androgen-independent disease are still largely unknown.
Methods: We examined the gene expression profile in the LNCaP prostate cancer progression
model during chronic treatment with Casodex using cDNA microarrays consisting of 2305
randomly chosen genes.
Results: Our studies revealed a representative collection of genes whose expression was
differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown
to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This
set of highly expressed genes represents a signature collection unique to prostate cancer since their
expression was significantly greater than that of the collective pool of ten cancer cell lines of the
reference sample. The highly expressed signature collection included the hypoxia-related genes
membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3).
Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further
analyzed their expression and concluded that these genes may be involved in the molecular changes
that lead to androgen-independence in prostate cancer.
Conclusion: Our data indicate that one of the mechanisms of Casodex action in prostate cancer
cells is induction of hypoxic gene expression.
Background
Prostate cancer remains the second leading cause of can-
cer death in men. The progression of prostate cancer from
an androgen-dependent, treatable stage to an androgen-
independent, non-curable stage is still the primary cause
of mortality. Despite screening for early diagnosis, it is
still not possible to determine which patients will
progress to the androgen-independent stage [1]. Andro-
gen-dependent prostate cancer is responsive to androgen-
ablation therapy and the cancer cells die by apoptosis [2].
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through the androgen receptor has been the cornerstone
of treatment of advanced prostate cancer [3].
Casodex is a non-steroidal anti-androgen commonly used
in the treatment of prostate cancer. Treatment of patients
with Casodex has been shown to decrease the progression
of early stage prostate cancer to the advanced stages [4].
One of the issues in androgen-blockade therapy is the
occurrence of androgen-independent cells which are
thought to be the predominant cell type after relapse from
therapy. These androgen-independent cells often express
mutations in the androgen receptor which accounts for
their lack of response to anti-androgens. Recently, it was
shown that treatment of patients with Casodex did not
result in the occurrence of cells expressing androgen
receptor mutations [5]. In our studies, Casodex was cho-
sen since this anti-androgen was shown to act as an andro-
gen receptor antagonist in LNCaP cells. LNCaP cells
express a mutation in the hormone binding domain
which causes these cells to be stimulated by other anti-
androgens [6]. Other studies have shown that Casodex
can act as an agonist in prostate cancer [7].
cDNA microarray analysis has become a powerful tool to
measure global gene expression changes in both patient
biopsy samples and cell culture models. The ability to
quantitatively measure differential gene expression pro-
vides an opportunity to compare differences in samples
which identify potential pathways and modulators of dis-
ease processes [8]. A recent study measured differences in
gene expression in patient samples and found a clear dif-
ference between prostate cancer and benign prostatic
hyperplasia [9]. Another study examined differences in
gene expression in prostate cancer cell lines and found a
unique set of genes whose expression was up regulated
[10]. Yet another study showed expression of the
enhancer of zeste homologue 2 (EZH2), a polycomb
group protein, was overexpressed in androgen-independ-
ent prostate cancer and may be a potential modulator of
progression [11].
An unusual high tolerance of cancer tissues to low oxygen
conditions was one of the first observations regarding can-
cer cells [12]. The significance of hypoxia in cancer has
only recently become a focus of many studies. Recently, it
was suggested that expression of hypoxic genes may be
responsible for the progression to malignancy in prostate
cancer [13]. It was also shown that the more hypoxic a
prostate tumor in a patient, the more likely the patient
was to experience therapy failure [14]. It has also been
suggested that the mechanism of prostate cell death upon
androgen withdrawal is due to apoptosis induced by
ischemia and hypoxia [15].
In this study we utilized the previously described LNCaP
prostate cancer progression model [16,17] to address
changes in gene expression that accompany the progres-
sion to androgen-independence. Our previous studies
showed that chronic treatment of LNCaP-R and LNCaP-
UR cells with Casodex selected for cells resistant to apop-
tosis induction [18]. In the present study, we utilized
cDNA microarray analysis to measure the changes in gene
expression that had occurred in the LNCaP model after
treatment with Casodex to identify potential modulators
of prostate cancer progression. We used low passage,
androgen-dependent, LNCaP-R cells and high passage,
androgen-independent, LNCaP-UR cells and treated cells
with Casodex for five weeks to mimic chronic treatment in
patients. Our results indicate a set of highly expressed
genes that may serve as a signature for prostate cancer pro-
gression. A subset of these highly expressed genes were the
hypoxia-related genes membrane metallo-endopeptidase
(MME), cyclin G2, and Bcl2/adenovirus E1B 19 kD (B-cell
lymphoma nineteen kDa interacting protein, BNIP3).
This study identifies for the first time the novel pathway of
hypoxic gene expression that may modulate the progres-
sion of prostate cancer to the androgen-independent state
and demonstrate the induction of hypoxia as a mecha-
nism of Casodex action.
Methods
Chemicals and reagents
Bicalutamide (Casodex) was provided by AstraZeneca
(UK) and was dissolved in fresh dimethylsulfoxide
(DMSO) to a concentration of 50 mM, divided into aliq-
uots, and stored at -20°C until further use. Normal
human prostate epithelial cell RNA (PrEC) was purchased
from Clonetics (Rockland, ME). RPMI 1640, Dulbecco's
Modified Essential Media (DMEM), fetal bovine serum
(FBS), penicillin-streptomycin (PS), TRIzol, and Hank's
Balanced Salt Solution (HBSS) were purchased from Life
Technologies (San Diego, CA). Total human reference
RNA was purchased from Stratagene (La Jolla, CA).
Cell culture
LNCaP cells were maintained in RPMI 1640 supple-
mented with 7% FBS and 1% PS. DU145 and PC3 cells
were grown in DMEM supplemented with 5% FBS and
1% PS. Treatment of LNCaP cells with Casodex was per-
formed as follows: Cells were seeded into T75 flasks in
RPMI 1640 with 7% FBS and 1% PS and allowed to grow
to 70% confluence. The media was then removed and
replaced with RPMI 1640 with 7% FBS and 1% PS media
containing 1 µM Casodex (vehicle 0.01%). Control cells
were fed with media and passaged as needed. Cells grown
in media containing Casodex were fed once every three
days but did not require passaging during the five-week
treatment.Page 2 of 15
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RNA was isolated from cells using TRIzol according to
manufacturer's instructions. Briefly, media were removed
and cells were rinsed once in HBSS. A volume of 3 ml of
TRIzol was added to each T75 flask and cells were scraped
and placed into tubes for chloroform phase separation.
RNA was precipitated using isopropanol, rinsed with 70%
ethanol in diethylpyrocarbonate water (DEPC), and
resuspended in RNase free water. The quality and quantity
of RNA was determined using RNA 6000 Nano chips on
the Agilent 2100 Bioanalyzer (Agilent Technologies).
Array fabrication
The slides used in this study were generated as follows:
cDNA inserts from Research Genetics Sequence Verified
Human cDNA library were amplified using standard pro-
cedures in a 96-well format, each well containing 100 µl
of PCR reaction mix and 1 µl of bacterial culture as the
template. The reaction buffer contained 1.5 mM MgCl2,
1× PCR buffer, 0.2 mM dNTPs, 0.25 mM primers, 2.5
units Taq DNA polymerase, and 0.2 % Tween 20. Follow-
ing an initial denaturation step of 94°C for 60 seconds, 33
cycles of 94°C for 45 seconds, 55°C for 45 seconds, and
72°C for 180 seconds was performed. Verification of the
amplified PCR products was performed by agarose gel
electrophoresis. Individual PCR products were precipi-
tated overnight at -20°C with sodium acetate (pH 5.2)
and ethanol. Following precipitation, the DNA pellets
were allowed to dry at room temperature and were resus-
pended by addition of 30 µl of 3× SSC and 0.1% sarcosyl
solution. This procedure resulted in a concentration range
of 100 to 499 ng/µl of DNA per sample. The PCR products
were spotted 2,305 spots at 375 µm spacing / 2.2 cm2 / per
slide onto poly-L-lysine-coated microscope slides using
an Affymetrix GMS 417 arrayer per manufacturer's sugges-
tions at 50% humidity and 25°C. The slides were allowed
to dry overnight before the DNA was cross-linked to the
slides by UV irradiation.
Probe synthesis and hybridization
A total of 20 µg RNA from each control and treated sam-
ples were reverse transcribed in the presence of amino-
allyl modified dUTP [5-(3-aminoallyl)-2'-deoxyuridine 5
triphosphate] and indirectly labeled with cyanine 3 (cy 3)
or cyanine 5 (cy 5) dye using the FairPlay microarray labe-
ling kit (Stratagene) according to manufacturers instruc-
tion. The absorbance of the samples was measured at 260
nm (for cDNA), 550 nm (for cy 3), 650 nm (for cy 5) to
give an indication of reverse transcription and dye labe-
ling efficiency. Cy3 and cy5 labeled samples were mixed
with 20 µg human Cot 1 DNA (Stratagene) and 20 µg
poly-adenine (Sigma) and the samples were dried in a
speed vacuum on medium heat for 2 hours. Dried sam-
ples were resuspended in 18 µl of hybridization buffer
containing 50% formamide, 5× sodium chloride and
sodium citrate (SSC), and 0.1% sodium dodecyl sulfate
(SDS). The samples were denatured by incubation at
95°C for 3 minutes then placed on ice for 30 seconds.
Slides were prehybridized by incubation for 1 hour at
42°C in prehybridization buffer containing 1.0% bovine
serum albumin (BSA), 0.1% SDS, and 5× SSC. The slides
were rinsed three times in milli Q water, dipped into 99%
isopropanol, and air-dried. Labeled probes were hybrid-
ized for 16 hours in a 42°C water bath. Following hybrid-
ization, slides were sequentially washed for 5 minutes
each in buffers containing; 1× SSC and 0.2% SDS, 0.1×
SSC and 0.2% SDS, and 0.1% SSC. Slides were immedi-
ately scanned using a GenePix 4000A scanner (Axon
Instruments, Union City, CA).
Data extraction and analysis
Multi image tiff files generated using the GenePix 4000A
scanner were imported in GenePix Pro version 4 software
(Axon Instruments) for data extraction. Extraction of sig-
nal intensity data from each spot on the images was per-
formed and visually checked for accuracy. Raw fluorescent
intensities at 532 and 635 nm were measured and local
area background was subtracted from each spot using
GenePix Pro. Files generated from the extraction were
imported in Microsoft Excel for normalization. Trimmed
global median normalization was performed on the ratio
of medians. For data tables, candidate genes were chosen
according to fluorescent intensity readings at 635 nm
above 400 units. Normalized ratios of the medians from
each of the three hybridizations were averaged and the
standard deviation was reported. Normalized, averaged
data sets were then analyzed using Cluster analysis and
visualized using Treeview [19].
RT-PCR
RNA transcripts were characterized by RT-PCR using
SuperScript II RNase H- Reverse Transcriptase (Invitrogen,
Life Technologies) according to manufacturer's instruc-
tions. Total RNA (5 µg) isolated from cells using TRIzol
was reverse transcribed to cDNA using oligo-dT primers.
The PCR product for hypoxia-inducible factor-1α (HIF-
1α) was amplified using the following primers: F: 5'-CCT-
TCGATCAGTTGTCACCA-3' and R: 5'-TGGGTAGGAGAT-
GGAGATGC and gave a 211 bp product. The PCR product
for membrane metalloendopeptidase (MME, also referred
to as CD10, CALLA, and NEP) was amplified as described
by Xiao et. al. [20] and gave a 268 bp product. For a con-
trol, β-actin was amplified in parallel using primers; F: 5'-
GAAGAGCTACGAGCTGCC-3', and R: 5'-TGATCCA-
CATCTGCTGGA-3' and gave a 368 bp product. Cyclin G2
primers were, F: 5'-AGCCATCAAATGGGGTAGTG-3', and
R: 5'-CTTGGGGCAATAGGAATGAA-3' and gave a product
of 502 base pairs. BNIP3 primers were; F: 5'-GCTCCT-
GGGTAGAACTGCAC-3', and R: 5'-TCTTCAT-
GACGCTCGTGTTC-3' and gave a 411 base pair product.Page 3 of 15
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42°C for 2 minutes, 42°C for 50 minutes, 70°C for 15
minutes, and hold at 4°C indefinitely. A volume of 5.0 µl
of the RT-PCR reaction product was added to each PCR
reaction with 1.0 µl each of forward and reverse primers.
The PCR cycling parameters used for Cyclin G2 and
BNIP3 were; Step 1, 95°C for 3.0 min; Step 2, 94°C for 1
min; Step 3, 60°C for 1 min; Step 4, 72°C for 45 sec; Step
5, repeat steps 2 through 4 thirty-five times; Step 6, 72°C
for 3 min; and Step 7, hold at 15°C until further use. The
PCR product of VEGF was amplified as described by Mun-
aut et al [21], Glut-1 was amplified as described by Ito et
al [22], and Carbonic anhydrase-IX and XII were ampli-
fied as described by Nishimori et al [23].
Real time PCR analysis
Quantitative Real Time PCR reactions were performed
using QuantiTect SYBR Green RT-PCR kit (Qiagen Inc.,
Valencia, CA) as per manufacturer's instructions. Each
reaction was set up with 1/10th the volume of cDNA gen-
erated by RT-PCR as described above. The PCR cycling
parameters used for HIF-1α are initial incubation of 95°C
for 15 minutes, 40 cycles of 95°C for 15 seconds, 60°C for
30 seconds, 72°C for 30 seconds, were performed. Reac-
tions, in duplicate, were performed on a BioRad iCycler
thermalcycler using iCycler software version 2.3v. The
comparative CT equation denotes the expression level of
the gene in a given sample, normalized with in the sample
to an endogenous reference gene and relative to the
expression level of the same gene in another sample can
be represented as ∆∆CT= [∆CT(sampleX)] - [∆CT(calibratorsam-
ple)] and ∆CT = [CT(targetgene)] - [CT(referencegene)] [24].
Western blot analysis
Protein extracts were prepared from cells using a protein
lysis buffer containing 50 mM Tris-HCl, pH 7.5, 2.0 mM
phenylmethylsulfonyl fluoride (PMSF), 5.0 mM iodoa-
cetamide, 5.0 mM ethylene diamine tetraacetic acid
(EDTA), 150 mM NaCl, 0.5% nonylphenoxy polyethoxy
ethanol (NP-40), and 0.5% nonanoyl-N-methylgluca-
mide (Mega-9). Protease inhibitors leupeptin (2 µg/ml)
and pepstatin (1 µg/ml) (Roche, Mannheim, Germany)
were added just prior to the addition of lysis buffer to the
cells. Protein concentrations in the extracts were quanti-
tated using bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL). From each extract, 10 to 50 µg of
total protein was separated on a 12% SDS-PAGE with a
5% stacking gel. After electrophoresis, proteins were trans-
ferred to 0.2 µm PVDF membranes (BioRad, Hercules,
CA) using transfer buffer that contained 25 mM Tris-HCl
and 700 mM glycine. Membranes were blocked in 7%
powdered milk dissolved in 1× TTBS (14 mM Tris, 154
mM NaCl, and 0.1% Tween-20, pH adjusted to 7.5 with
HCl) overnight at 4°C. Primary antibodies were incu-
bated for 2 hours at room temperature in 5% powdered
milk dissolved in 1× Tween-20 in TTBS. The antibody for
the mitochondrial import receptor protein (TOM20) was
provided by Dr. Masataka Mori, Kumamoto University
School of Medicine, Kumamoto, Japan. Primary antibod-
ies used were: polyclonal rabbit anti-human TOM20 at
1:1,500 dilution, polyclonal rabbit anti-human BNIP3
(BD Pharmingen, San Diego, CA) at 1:8,000 dilution; and
polyclonal goat anti-human Cyclin G2 (Santa Cruz Bio-
technology) at 1:1,500 dilution. The antigen-antibody
complexes were detected using the appropriate secondary
antibodies conjugated to horseradish peroxidase
(Promega, Madison, WI) dissolved in 1× TTBS with 5%
powdered milk and incubated with membranes for 1 hour
at room temperature. Membranes were developed using
ECL+ (Amersham Pharmacia Biotech, Arlington Heights,
IL) and films exposed for appropriate times to detect
signal.
Cell fractionation
The cytosolic and heavy membrane fractions of cells were
separated using the ApoAlert Cell Fractionation kit (Clon-
tech Laboratories, Palo Alto, CA) according to manufac-
turer's instructions. Briefly, cells were mechanically
dislodged and collected by centrifugation at 600 × g for 5
minutes at 4°C. The pellets were washed with 1 ml ice-
cold wash buffer, and resuspended in 800 µl of ice-cold
fractionation buffer. After incubation on ice for 10 min-
utes, cells were homogenized by 50 strokes using a
Dounce homogenizer (pestle B). The homogenates were
centrifuged at 700 × g for 10 minutes at 4°C. The superna-
tant was collected and further centrifuged at 10,000 × g for
25 minutes at 4°C. The resulting supernatant was desig-
nated as the cytosol fraction and the pellet (heavy mem-
brane fraction) was resuspended in 100 µl of fractionation
buffer mix. Protein concentrations in the extracts were
quantitated using bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL).
Results
Genes highly expressed upon Casodex treatment
To analyze the expression of genes that accompany the
progression of prostate cancer to the androgen-independ-
ent phenotype, we performed three separate cDNA micro-
array experiments, on androgen-dependent LNCaP-R and
androgen-independent LNCaP-UR cells cultured with or
without treatment for five weeks in 1 µM Casodex.
Hybridizations were performed against a common refer-
ence RNA pool so that comparisons across samples and
experiments could be made. The commercially available
common reference RNA pool contains RNA from ten dif-
ferent cancer cell lines. Of the 2305 genes examined, we
found 160 genes whose expression was altered at least 2-
fold in the treated cells.Page 4 of 15
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nificantly increased compared to the reference RNA and
Table 2 shows the fold change of these genes in response
to treatment with Casodex. These genes were overex-
pressed in all three hybridizations. After normalization
and filtering, a total of 160 genes from the samples were
analyzed using hierarchical clustering to show the similar-
ities of expression. The dendogram separated the samples
according to overall similarity and shows that control and
treated LNCaP-R samples reside on the same branch and
control and treated LNCaP-UR samples reside on a paral-
lel branch (Fig. 1). Of the 160 genes clustered were MME,
cyclin G2, and BNIP3 all of which showed differential reg-
ulation between the LNCaP-R and UR cells and all of
which clustered in a same node (Fig. 1). The correlation
coefficient of this node was 0.85 which suggests that the
expression pattern of these genes was 85% similar.
Hypoxia regulated gene expression in the LNCaP model 
treated with Casodex
HIF-1 is a transcriptional activator involved in oxygen
homeostasis in cells [25]. In tumors where hypoxic condi-
tions are common, HIF-1 levels are increased and stimu-
late gene expression that promotes angiogenesis [26].
HIF-1α is the inducibly expressed subunit that forms a
heterodimer with the constitutively expressed HIF-1β.
HIF-1α has been implicated in androgen-independent
prostate cancer [13] and is thought to mediate angiogen-
esis in tumors by transcriptional up regulation of vascular
endothelial growth factor [27]. BNIP3 was shown to be
regulated by HIF-1α [28,29] which led us to examine
whether the high levels of BNIP3 detected in our hybridi-
zations were accompanied by expression of HIF-1α. Fig-
ure 2 (panel A) shows the results of an RT-PCR and reveals
the expression of HIF-1α in normal human prostate
Table 1: Highly expressed Casodex responsive genes in the LNCaP model. Data show fold-increase in gene expression over reference 
samples. Each datum point represents mean ± SE from 3 independent experiments.
LNCaP-R LNCaP-UR
GenBank # Name Control ± SE Treated ± SE Control ± SE Treated ± SE
AA663884 synaptosomal-associated protein 15.18 ± 3.35 20.67 ± 9.33 20.92 ± 1.07 11.68 ± 0.61
AA700604 sorbitol dehydrogenase 13.73 ± 3.23 19.60 ± 6.50 21.08 ± 1.58 11.08 ± 1.39
T73556 fatty-acid-Coenzyme A ligase 5.11 ± .34 2.45 ± 0.74 3.94 ± 0.46 1.07 ± 0.25
AA028987 EST 5.38 ± 6.95 8.43 ± 5.68 6.22 ± 2.05 11.00 ± 3.74
R98851 membrane metallo-endopeptidase 10.28 ± 5.90 55.90 ± 30.2 79.29 ± 16.62 153.50 ± 56.07
N68465 UDP-N-acteylglucosamine pyrophosphorylase 4.37 ± 3.73 3.99 ± 1.44 12.47 ± 2.03 9.03 ± 2.41
H84113 retinal outer segment membrane 1 8.03 ± 2.06 14.73 ± 4.93 9.79 ± 1.39 7.09 ± 0.65
AA041499 cell division cycle 4-like 11.66 ± 7.07 10.67 ± 1.84 3.47 ± 0.44 3.64 ± 1.14
AA456695 H2B histone family, member Q 4.67 ± 3.02 4.23 ± 1.14 2.56 ± 0.27 4.67 ± 1.13
R82299 S-adenosylmethionine decarboxylase 1 8.35 ± 2.23 14.84 ± 4.06 11.11 ± 2.19 6.98 ± 0.51
AA063521 BCL2/adenovirus E1B 19 kD 3.59 ± 3.34 13.14 ± 3.94 6.76 ± 1.79 12.46 ± 2.32
AA419164 retinoic acid receptor, beta 9.90 ± 3.40 11.14 ± 2.23 7.44 ± 0.98 5.01 ± 0.46
AA459039 serine protease inhibitor, Kunitz type, 2.89 ± 2.90 10.44 ± 1.46 6.28 ± 0.99 9.94 ± 1.44
AA489752 cyclin G2 2.86 ± 2.67 10.97 ± 1.10 6.92 ± 1.62 15.14 ± 4.80
AA412053 CD9 antigen (p24) 4.80 ± 1.05 8.78 ± 2.72 5.44 ± 0.96 6.12 ± 0.84
Table 2: Gene expression fold change in the LNCaP model treated with Casodex.
Fold Change
GenBank# Name LNCaP-R Control vs. Treated LNCaP-UR Control vs. Treated
T73556 fatty-acid-Coenzyme A ligase - 2.09 - 3.68
R98851 membrane metallo-endopeptidase + 5.44 + 1.94
AA063521 BCL2/adenovirus E1B 19 kD + 3.66 + 1.84
AA459039 serine protease inhibitor, Kunitz type, + 3.61 + 1.58
AA489752 cyclin G2 + 3.84 + 2.19
(+, fold up regulated and -, fold downregulated)Page 5 of 15
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Cluster diagram of LNCaP cells treated with Casodex. Clustering was performed as described in Materials and Meth-
ods. LNCaP-R C, control. LNCaP-R T, treated 5 weeks in 1 µM Casodex. LNCaP-UR C, control. LNCaP-UR T, treated 5 
weeks in 1 µM Casodex. Columns, individual samples and rows, individual genes. Cells represent the expression level of the indi-
cated gene where green is downregulated, red is up regulated, black is zero, and gray is missing. The correlation in this node is 
0.85.Page 6 of 15
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A. RT-PCR of HIF-1α. RT-PCR was performed as described in Materials and Methods and shows the presence of HIF-1α 
(upper panel) and β-actin as internal control (lower panel). Lane 1, normal prostate (PrEC). Lanes 2 and 3, androgen-independ-
ent prostate cell lines PC3 and DU145, respectively. Lane 4, LNCaP-R control. Lane 5, LNCaP-R treated 5 weeks in 1 µM 
Casodex. Lane 6, LNCaP-UR control. Lane 7, LNCaP-UR treated 5 weeks in 1 µM Casodex. B. Quantitative real time PCR for 
HIF-1α expression was perfomed as described in materials and methods. CT values was determined using the formula ∆∆CT = 
[∆CT(sampleX)] - [∆CT(calibratorsample)] and ∆CT = [CT(targetgene)] - [CT(referencegene)]. The graph was drawn using Graph Pad Prism 
3.0.Page 7 of 15
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model. Using RT-PCR, we did not observe significant dif-
ferences in the intensity of the PCR band between differ-
ent cell lines and upon treatment with Casodex. To more
quantitatively assess the message level, we performed a
quantitative Real Time PCR analysis of HIF-1α along with
β-actin as an internal control. The data presented in Figure
2 (panel B) shows a clear up regulation of HIF-1α expres-
sion in the androgen-independent PC3 and DU145 cells
when compared to the low levels expressed in normal
prostate epithelial cells (PrEC). In the LNCaP model, low
levels of HIF-1α are expressed in the untreated LNCaP-R
and LNCaP-UR cells. However, upon Casodex treatment,
both LNCaP-R and UR cells show increased expression of
HIF-1α which more closely resembles the expression pat-
tern observed in the androgen-independent PC-3 and
DU-145 cells.
Verification of MME, Cyclin G2, and BNIP3 message in the 
LNCaP model
MME is a neutral endopeptidase expressed on the cell sur-
face and catalyzes the degradation of biologically active
neuropeptides [30]. Prostate epithelial cells express MME,
including the LNCaP prostate cancer cell line, and there is
evidence that the presence of MME on the surface of pros-
tate cancer cells promotes metastasis [31,32]. In contrast,
other reports suggest that MME can inhibit prostate cancer
cell growth [33] and can inhibit prostate cancer cell migra-
tion [34] and loss of MME expression can contribute to
the progression to androgen-independence [35]. MME
was shown to be up regulated at the transcriptional level
by androgen in LNCaP prostate cancer cells [36]. RT-PCR
was performed to verify message expression of MME.
Figure 3 shows the results of RT-PCR of MME in normal
human prostate epithelial cells, PC3 and DU145 cells,
and the LNCaP model control and treated with Casodex.
The data show a single product of expected size (268 bp)
in all samples tested. As a normalization control, we
included β-actin in parallel experiments (Figure 3, panel
B). MME protein was reported to be undetectable in PC3
and DU145 cells [32]. However, our results show that
MME message was expressed in PC3, DU145 and LNCaP
cells.
RT-PCR of MMEFigure 3
RT-PCR of MME. RT-PCR was performed as described in Materials and Methods and confirms the presence of MME. A sin-
gle band at 268 bp (black arrow) indicates MME message expression. Lane 1, normal prostate (PrEC). Lanes 2 and 3, androgen-
independent prostate cell lines PC3 and DU145, respectively. Lane 4, LNCaP-R control. Lane 5, LNCaP-R treated 5 weeks in 1 
µM Casodex. Lane 6, LNCaP-UR control. Lane 7, LNCaP-UR treated 5 weeks in 1 µM Casodex. β-actin (bottom panel) was 
included as a control.Page 8 of 15
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induced during apoptosis. Cyclin G2 is expressed at vary-
ing levels through the cell cycle and was shown to be
present in cerebellum, thymus, spleen, kidney and pros-
tate tissue [38]. Interestingly, cyclin G2 was recently
shown to be induced by hypoxia [39]. Figure 4 verifies
cyclin G2 message expression (product at 502 bp) in the
LNCaP cells treated or untreated with Casodex. RT-PCR
confirmed the presence of cyclin G2 in control and treated
LNCaP cells. However, western blot analysis showed that
Casodex-treated cells overexpressed cyclin G2 protein
(Figure 5). Figure 5 shows protein levels of cyclin G2 in
LNCaP cells treated or untreated with Casodex. Cyclin G2
protein levels appear to be up regulated upon treatment
with Casodex in both the LNCaP-R (lane 2) and LNCaP-
UR (lane 4) cells. These results are consistent with cyclin
G2 message up regulation indicated in microarray analy-
sis (Table 2).
BNIP3 is a proapoptotic Bcl-2 family member localized to
the mitochondrial membrane and was shown to interact
with antiapoptotic family members to promote apoptosis
RT-PCR of Cyclin G2Figure 4
RT-PCR of Cyclin G2. RT-PCR was performed as described in Materials and Methods and confirms the presence of Cyclin 
G2 message expression in LNCaP cells control or treated with 1 µM Casodex for 5 weeks. Cyclin G2 message is indicated 
(black arrow) at 502 bp. Lane 1, LNCaP-R control. Lane 2, LNCaP-R treated 5 weeks in 1 µM Casodex. Lane 3, LNCaP-UR 
control. Lane 4, LNCaP-UR treated 5 weeks in 1 µM Casodex.
Western blot of Cyclin G2Figure 5
Western blot of Cyclin G2. Western blot was performed as described in Materials and Methods and shows the presence of 
Cyclin G2 (CCNG2) protein in LNCaP cells control or treated with 1 µM Casodex for 5 weeks. Lane 1, LNCaP-R control. 
Lane 2, LNCaP-R treated 5 weeks in 1 µM Casodex. Lane 3, LNCaP-UR control. Lane 4, LNCaP-UR treated 5 weeks in 1 µM 
Casodex.Page 9 of 15
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protein to the mitochondrial membrane and it was shown
that deletion mutants lacking the transmembrane region
were unable to induce apoptosis [40]. BNIP3 was shown
induce apoptosis in hypoxic cardiac cells. [41-43] and is
itself induced by hypoxia in tumors [29]. Figure 6 verifies
by RT-PCR BNIP3 message expression (411 bp) in the
LNCaP model control and treated with Casodex. RT-PCR's
were repeated for each MME, cyclin G2, and BNIP3 bio-
logical replicates and similar results were observed (data
not shown).
BNIP3 in the LNCaP model treated with Casodex
In order to assess the significance of BNIP3 message up
regulation in the LNCaP model, we performed western
blots to determine the subcellular localization of the pro-
tein. Cytosolic and mitochondrial fractions were sub-
jected to western blot analysis and TOM20, an integral
mitochondrial membrane protein [44], was included as
an internal control. Figure 7 shows that BNIP3 was
detected in the mitochondrial fraction of both LNCaP-R
and UR cells (lanes 2, 4, 6, and 8), and BNIP3 is overex-
pressed in the Casodex-treated LNCaP-R and LNCaP-UR
cells.
Expression of other hypoxia-related genes
In order to determine if other hypoxia-related genes were
being regulated in the LNCaP model treated with Caso-
dex, we measured mRNA expression levels of vascular
endothelial growth factor (VEGF), glucose transporter-1
(Glut-1), and carbonic anhydrases 9 and 12 (CAIX and
CAXII). VEGF isoforms 189, 165, and 121 are shown in
Fig. 8, panel A. We did not detect a band representative of
VEGF isoform 145. Isoform 121 showed relatively equal
expression in all cells tested however, isoform 165
appeared upregulated in LNCaP-R cells after five weeks
treatment with Casodex (Fig. 8 panel A. lane 5). Isoform
189 appeared upregulated in DU145 cells (lane 2) com-
pared to PC3 cells (lane 1) and increased in LNCaP-R and
UR cells after treatment with Casodex (lanes 5 and 7,
respectively). Increased glucose uptake, mediated by Glut-
1, is thought to protect cells from apoptosis in hypoxic
conditions [45]. Expression levels of Glut-1 are shown in
Fig. 8 panel B and shows basal levels of Glut-1 in PC3 and
DU145 cells (lanes 1 and 3). Treatment of LNCaP-R and
UR cells with Casodex resulted in an upregulation of Glut-
1 message (lanes 5 and 7, respectively). CAIX and XII are
inducible by HIF-1α [39] and were shown to be expressed
at very low levels in PC3 cells and negative for expression
in DU145 cells [46]. Fig. 8 panel C shows CAIX expression
is barely detectable in PC3, DU145, LNCaP-R control and
treated with Casodex (lanes 2 through 5). LNCaP-UR cells
showed an approximate two-fold increase in CAIX
expression after treatment with Casodex (lanes 6 and 7).
CAXII expression was detected in both PC3 and DU145
cells (Fig. 8, panel D, lanes 1 and 2), however, in LNCaP-
R cells treated with Casodex, the levels appeared to
decrease approximately two-fold (lanes 4 and 5). LNCaP-
UR cells showed approximate equal expression of CAXII
after treatment with Casodex (lanes 6 and 7).
RT-PCR of BNIP3Figure 6
RT-PCR of BNIP3. RT-PCR was performed as described in Materials and Methods and confirms the presence of BNIP3 mes-
sage expression in LNCaP cells control or treated with 1 µM Casodex for 5 weeks. BNIP3 message expression is indicated 
(black arrow) at 411 bp. Lane 1, LNCaP-R control. Lane 2, LNCaP-R treated 5 weeks in 1 µM Casodex. Lane 3, LNCaP-UR 
control. Lane 4, LNCaP-UR treated 5 weeks in 1 µM Casodex.Page 10 of 15
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In this study, cDNA microarray analysis was performed to
identify genes involved in prostate cancer cell response to
chronic treatment with Casodex. The LNCaP prostate can-
cer progression model was used due to its ability to
progress from an androgen-dependent to an androgen-
independent phenotype [17]. With this model, it was
possible to measure changes in gene expression that
accompanied progression from androgen-dependence to
androgen-independence in a similar genetic background
in response to chronic treatment with Casodex. Since
patients with both androgen-dependent and androgen-
independent prostate cancer are treated with androgen-
ablation therapy, it is important to understand what
changes in gene expression occur in both cases in order to
identify potential therapeutic targets for more specific
intervention independent of androgen-signaling status.
The treatment time course of LNCaP in Casodex contain-
ing media was based on pilot studies which showed no
change in the antiapoptotic protein Bcl-2 after growth of
the cells for three weeks. After five weeks in Casodex con-
taining media, there was an apparent decrease in Bcl-2
protein and we measured a decrease in apoptosis [18]. We
surmised from these studies that the changes occurring in
LNCaP cells resulted after extended exposure to Casodex
and therefore, set the time course of five weeks treatment.
The three independent microarray analyses consistently
showed a set of highly expressed genes (Table 1). Given
that the reference RNA contained a set of 10-pooled can-
cer cell lines, we termed these highly expressed genes as
"prostate cancer signature genes". We chose to further
examine expression of MME, cyclin G2, and BNIP3 since
these genes were significantly up regulated in the LNCaP
model upon treatment with Casodex (Table 2) and these
genes are each involved in hypoxia-response.
Several genes showed downregulated expression in
response to Casodex treatment in LNCaP-UR cells (Table
1) however, only fatty-acid-Coenzyme A ligase showed
downregulated expression in both LNCaP-R and UR cells
Cell fractionation and western blot of LNCaP cells treated with CasodexFigure 7
Cell fractionation and western blot of LNCaP cells treated with Casodex. Cell fractionation of cytosolic (Cyto) and 
mitochondrial (Mito) fractions and western blot was performed as described in Materials and Methods. LNCaP cells either 
treated with 1 µM Casodex for 5 weeks or control were fractionated and subjected to western blot and show that LNCaP-UR 
cells overexpress BNIP3 which is predominately localized in the mitochondrial fraction. Lane 1, LNCaP-R control cytosolic 
fraction. Lane 2, LNCaP-R control mitochondrial fraction. Lane 3, LNCaP-R treated with 1 µM Casodex for 5 weeks, cytosolic 
fraction. Lane 4, LNCaP-R treated with 1 µM Casodex for 5 weeks, mitochondrial fraction. Lane 5, LNCaP-UR control 
cytosolic fraction. Lane 6, LNCaP-UR control mitochondrial fraction. Lane 7, LNCaP-UR treated with 1 µM Casodex for 5 
weeks, cytosolic fraction. Lane 8, LNCaP-UR treated with 1 µM Casodex for 5 weeks, mitochondrial fraction. TOM20, a mito-
chondrial integral membrane protein, (bottom panel) was included as a control.Page 11 of 15
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RT-PCR of HIF-1 induced genes. LNCaP cells were treated with 1µM Casodex for 5 weeks. RNA was isolated from both 
treated and untreated cells as described in Materials and Methods. Expression of VEGF isoforms (panel A), Glut-1 (panel B), 
CA-IX (panel C), CA-XII (panel D) and β-Actin (panel E) were examined by RT-PCR. In each panel, the cell lines shown are 
PC-3 (lane 2), DU-145 (lane 3) LNCaP-RC (lane 4), LNCaP-RT (lane 5), LNCaP-URC (lane 6) and LNCaP-URT (lane 7). The 
100 bp DNA ladder (lane1) is included as a size marker. PCR amplification was performed as described under Materials and 
Methods.Page 12 of 15
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downregulation, it is possible that hypoxic conditions
resulted in fatty-acid metabolism alterations which
caused the downregulation of this ligase.
Clustering of the 160 genes showed that MME, cyclin G2,
and BNIP3 were similarly expressed (Fig. 1) and clustered
in a similar node (correlation = 0.85) which supports the
notion that a hypoxic response is a predominant
phenomena in LNCaP cells response to treatment with
Casodex. The dendogram in Figure 1 revealed the similar-
ities and differences between representative cell lines in
our LNCaP model. Control and treated LNCaP-R samples
clustered in the same branch and in parallel, control and
treated LNCaP-UR samples clustered in the same branch
(Fig.1). Since LNCaP-R and LNCaP-UR cells differ in
terms of growth, morphology, response to androgen, and
sensitivity to apoptosis [16], it was expected the two
would cluster in separate branches. These data demon-
strate the distinct genetic expression profiles largely due to
the androgen-dependent and androgen-independent dif-
ference between LNCaP-R and LNCaP-UR cells.
We probed for HIF-1α expression by RT-PCR. The results
showed the presence of HIF-1α at the expected molecular
weight in all cells. Quantitative PCR analysis indicated up
regulation of HIF-1α in Casodex treated LNCaP-R and
LNCaP-UR cells (Figure 2, panel B). This result is
consistent with up regulation of hypoxia-related genes
upon treatment with Casodex (Tables IA and IB). Further,
up regulation of HIF-1α in the Casodex-treated cells is
similar to the high levels of HIF-1α in the androgen-inde-
pendent PC3 and DU145 cells, indicating that Casodex
treatment may drive the LNCaP cells towards androgen-
independence, consistent with our previous observations
[18].
We verified the identity and expression of some of the
genes identified by microarray analysis and relevant to
hypoxia. MME, cyclin G2, and BNIP3 message identity
and expression were confirmed by RT-PCR analysis (Figs.
3, 4, and 6, respectively). MME has been implicated in
prostate cancer and though the data are conflicting on
whether this gene promotes or protects against the pro-
gression, our data suggest a role for this gene in prostate
cancer progression to androgen-independence. Though
others report that MME was not detectable in PC3 and
DU145 cells [29]. This disparity may be due to subtle dif-
ferences in culturing techniques or PCR conditions
between our laboratory and others working with these
cells. In the LNCaP-R cells, MME expression was up regu-
lated over 5-fold and in LNCaP-UR cells MME was up
regulated nearly 2-fold in response to Casodex (Table 2).
In context, MME was up regulated over 150-fold in the
LNCaP-UR cells compared to the reference RNA (Table 1)
which strongly suggests this gene plays a role in androgen-
independent prostate cancer. Precisely what function
MME plays in the LNCaP model is currently under
investigation.
Cyclin G2 was shown to inhibit cell cycle progression and
promote apoptosis [37]. Our data showed an increase in
cyclin G2 message (Table 2) and protein expression (Fig.
5, lanes 2 and 4) in the LNCaP model upon treatment
with Casodex. Aside from the known induction of cyclin
G2 by HIF-1α [39] the increased expression of cyclin G2
in our Casodex treated samples could also be due to the
long duration of time the cells spend in the culture flask.
The experiment warrants that Casodex treatment begins
after the cells have come to approximately 70% conflu-
ence. At this density, there is a short time period after the
addition of media containing Casodex of sustained loga-
rithmic growth after which the cells appear to cease
growth before the 5 weeks treatment has ended (visual
inspection, data not shown). It is possible that cyclin G2
is involved in the growth arrest observed in the LNCaP
model during treatment with Casodex.
BNIP3 is a proapoptotic Bcl-2 family member and as such,
its up regulation and overexpression would predict induc-
tion of apoptosis. We have previously shown that in
LNCaP cells treated with 1 µM Casodex for 5 weeks then
treated with 5 nM docetaxel, the cells pretreated for 5
weeks in Casodex exhibited an increased resistance to the
induction of apoptosis by docetaxel when compared to
cells not pretreated with Casodex but treated with
docetaxel [18]. We addressed the possibility that BNIP3
protein may be missorted or mutated. It was shown that
C-terminal deletion mutants of BNIP3 lost the ability to
induce apoptosis [40]. We did detect the presence of
BNIP3 in the mitochondrial membrane fraction of cells
suggesting that BNIP3 is localized correctly to the mito-
chondrial membrane presumably via its C-terminal trans-
membrane region. Determining why the increased levels
of BNIP3 do not induce apoptosis in the LNCaP model is
currently under investigation.
Expression of VEGF isoforms 165 and 121 showed similar
levels in LNCaP-R and UR cells treated with Casodex.
However, the 189 isoform appeared to be upregulated
upon treatment with Casodex. The 189 isoform may be
preferentially induced in response to Casodex in the
LNCaP model. The absence of VEGF isoform 145 in all
cells tested suggest either that it is not a preferred
expressed isoform in prostate cancer cells or that our PCR
cycling conditions did not favor its expression though this
latter possibility is unlikely since the primers used were
designed to amplify all four splice variants. Glut-1 expres-
sion levels showed upregulation in the LNCaP model after
treatment with Casodex suggesting that the cells werePage 13 of 15
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ing glucose uptake to protect against hypoxia-induced
damage. CAIX and XII showed variable expression (Fig. 8.
panels C and D) with CAIX detected only in the LNCaP-
UR cells. CAXII showed variable expression in all cells and
was downregulated in LNCaP-R cells treated with Casodex
(Fig. 8 panel D, lane 5) but appeared unchanged in
LNCaP-UR cells after treatment (lanes 6 and 7). These
data suggests that CAIX and XII may not be major contrib-
utors in LNCaP cells response to Casodex treatment.
It was recently shown, using the LNCaP prostate cancer
cell line, that one of the mechanisms of Casodex in pros-
tate cancer was the assembly of an inactive transcriptional
complex on androgen response elements in the DNA sug-
gesting that altered coactivator and/or corepressor genes
may be responsible for androgen-independent progres-
sion [47]. Our data showing differential expression of
hypoxia related genes up regulated upon treatment with
Casodex are supported by this finding.
Conclusion
We conclude from these studies that hypoxia plays a criti-
cal role in the progression of prostate cancer to the andro-
gen-independent phenotype and furthermore, identify
induction of a hypoxic response as one of the mechanisms
of Casodex in prostate cancer.
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